TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00856700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-1 infusion
Description: Participants will receive intraarterial infusion of GLP-1 (20 pmol/ml solution) for 100 min.
Study: NCT01697683

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic Lactobacilli
Description: Two capsules per day containing either probiotic lactobacilli or placebo for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01310166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fingolimod
Study: NCT03733275

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine
Description: for experimental arm, lidocaine spray and lidocaine bupivacine mixture-soaked nasal packing vs. for placebo arm, normal saline spray and packing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: for experimental arm, lidocaine spray and lidocaine bupivacine mixture-soaked nasal packing vs. for placebo arm, normal saline spray and packing
Study: NCT03478969

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accu-Chek® Solo micropump system
Description: Medical device for subcutaneous delivery of insulin in a personalized way.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accu-Chek® Solo micropump system
Description: Medical device for subcutaneous delivery of insulin in a personalized way.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accu-Chek® Solo micropump system
Description: Medical device for subcutaneous delivery of insulin in a personalized way.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mylife™ OmniPod® Insulin Management System
Description: A patch pump system delivering insulin.
Study: NCT03374800

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (0.9% saline)
Description: normal saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole
Description: 40 mg powder for injection reconstituted with 0.9% saline
Study: NCT02793505

Intervention type: DRUG
Intervention: any drug not known as a major teratogen or major fetotoxicant
Description: This is not an intervention but an observed exposure.
Study: NCT01012310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04531083 or Placebo
Description: Subjects will receive multiple oral doses of less than or equal to 100mg PF-04531083 or placebo for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04531083 or Placebo
Description: Subjects will receive multiple oral doses of less than or equal to 300mg PF-04531083 or placebo for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04531083 or Placebo
Description: Subjects will receive multiple oral doses of less than or equal to 500mg PF-04531083 or placebo for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04531083 or Placebo
Description: A fourth cohort may be used to investigate alternative dosing regimens, formulations or food effects.
Study: NCT01689701

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo(1.3g/d)
Study: NCT01605877

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0]
Description: Multifocal IOL with extended secondary focal point implanted for long-term use over the lifetime of the cataract patient
Study: NCT03854305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRV-6527
Description: Treatment
Study: NCT02473523

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PedsQL Cancer Module
Description: The PedsQL cancer module acute version is a 27 item assessment that includes eight scales including pain (2 items), nausea (5 items), anxiety related to procedures (3 items), anxiety related to treatment (3 items), worry (3items), cognitive problems (5 items), perceived physical appearance and communication (3 items). This assessment will take approximately 15-30 minutes to complete.
Study: NCT03854305

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Comparator
Study: NCT03478969

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multiple Daily Injections (MDI) therapy
Description: Injecting insulin as per participant's need.
Study: NCT00759798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25 mg/m\^2 given intravenously on Days 2-4 of Cycle 1 and Days 1-3 of Cycles 2 and beyond.
Study: NCT02473523

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PedsQL Multidimensional Fatigue Scale
Description: The Multidimensional Fatigue Scale is an 18 item questionnaire encompassing 3 subscales including general fatigue (6 items), sleep and rest fatigue (6 items) and cognitive fatigue (6 items). This assessment will take approximately 10-20 minutes to complete.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biodex System 3 Dynamometer
Description: The Biodex System 3 Dynamometer will be used to measure isometric quadriceps muscle contractions. Participants will be stabilized in the chair with abdominal and shoulder straps. The isometric tests for knee extension will be done on both dominant and non-dominant leg. The tests consist of 3 maximal muscle contractions each lasting five seconds separated by 40 second rest intervals. This assessment will take approximately 10 minutes to complete.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jamar Hydraulic Hand Dynamometer
Description: A calibrated Jamar hydraulic hand dynamometer will be used to measure grip strength. The participant will be seated in a chair with elbow flexion to 90 degrees against torso and the forearm in neutral. The participant will grasp the device and the handle will be adjusted so that digits are able to comfortably grasp the device. The maximum score after 2 trials will be recorded as grip strength for both right and left hand. This assessment will take no more than 5 minutes to complete.
Study: NCT00759798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 250 mg/m2 given intravenously on Days 2-4 of Cycle 1 and Days 1-3 of Cycles 2 and beyond.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m2 given intravenously on Day 1 of Course 1~All subsequent Courses: 500 mg/m2 given intravenously on Day 1 (Weeks 5,9,13,17,21)
Study: NCT00864006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Divalproex Sodium

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depakote DR Tablets
Study: NCT02132520

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS
Description: Low frequency rTMS (either real or sham) will be applied to the contralesional hemisphere at a rate of 1Hz for 10 minutes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS
Description: Low frequency rTMS (either real or sham) will be applied to the contralesional hemisphere at a rate of 1Hz for 10 minutes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BCI Training
Description: BCI training will consist of a series of EEG-based motor-imagery tasks with virtual feedback presented on a computer screen.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: BCI Training
Description: BCI training will consist of a series of EEG-based motor-imagery tasks with virtual feedback presented on a computer screen.
Study: NCT03022968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]T807 PET
Description: Imaging with \[18F\]T807 PET

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]T807 PET
Description: Imaging with \[18F\]T807 PET

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]T807 PET
Description: Imaging with \[18F\]T807 PET
Study: NCT00859300

Intervention type: GENETIC
Intervention: Blood sample
Description: Blood sample Determination of genetic background

Intervention type: GENETIC
Intervention: Blood sample
Description: Blood sample Determination of genetic background
Study: NCT02797743

Intervention type: OTHER
Intervention: Whole blood
Description: * Adults ≥18 yrs of age: up to 50 mL (5 tubes)~* Adolescents 12-17 yrs of age: up to 30 mL (3 tubes)~* Children 0-11 yrs of age: single tube (1 tube, 10 mL)
Study: NCT02927249

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Given PO
Study: NCT02473523

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sit and Reach Test
Description: Hamstring flexibility will be assessed by the Sit and Reach Test. The sit and reach is a test to measure hip, hamstring and lower back flexibility. To measure flexibility participants will perform the YMCA sit and reach test. Participants will sit down without shoes or socks with the soles of their feet against the vertical platform of the sit-and-reach box located at the 26 cm (a little over 10 inches) mark. Participants keep their legs straight and their hands overlapped, while reaching for a less than maximum distance twice as a warm-up. This test will take no more than 5 minutes to complete.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Test of Motor Proficiency
Description: The Bruininks-Oseretsky Test of Motor Proficiency is a 9 item standardized assessment that includes standing with feet on a line with eyes open and closed, standing on a line with one foot with eyes open and closed, standing on a balance beam on one leg with eyes open and closed and standing heel to toe on a balance beam. These tests will be administered no more than two times with a maximum score of 10 seconds. Two additional subtests include walking forward on a line and walking heel to toe on a line for a maximum of 6 steps for both tasks. Total time to complete this test is approximately 10-20 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Verbal Numeric Pain Scale
Description: The verbal numeric pain scale will be administered before and after each yoga session. The principal investigator (PI) will ask the participant about his/her pain on a scale of 0-10 and the PI will record the number. This will take less than 10 seconds.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: :Yoga Therapy
Description: Those who consent will participate in 60-minute yoga sessions 2-3 times per week for 4-6 weeks. Only specified yoga poses will be implemented during the classes. Additional detail is included in the Description sections of this registration. The principal investigator is a Certified Yoga Therapist (CYT) and is a registered yoga teacher with 500 hours of training (RYT 500).
Study: NCT04038424

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Art therapy
Description: Art therapy including coloring, painting and listening to music
Study: NCT03673566

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NICU Dashboard
Description: The NICU Dashboard is displayed on a touch screen display mounted to the wall or on a rolling cart that will be placed near the bedside. The Dashboard will integrate information from various hospital/device sources in order to provide clinicians with one location to access and collectively interpret clinical findings and environmental factors. Parents will have their own view on the Dashboard that will allow them view their baby's progress, view educational materials, and have access to other resources at their fingertips.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NICU Dashboard
Description: The NICU Dashboard is displayed on a touch screen display mounted to the wall or on a rolling cart that will be placed near the bedside. The Dashboard will integrate information from various hospital/device sources in order to provide clinicians with one location to access and collectively interpret clinical findings and environmental factors. Parents will have their own view on the Dashboard that will allow them view their baby's progress, view educational materials, and have access to other resources at their fingertips.
Study: NCT00916760

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Depigoid Parietaria judaica 1000DPP/ml
Description: Subcutaneous monthly treatment
Study: NCT04638738

Intervention type: DEVICE
Intervention: SensiumVitals wearable patch sensor
Description: Wearable sensor which measures heart rate, respiratory rate, and temperature continuously.
Study: NCT01747304

Intervention type: DEVICE
Intervention: DXA Se femur scans (previously called IVA femur)
Description: Single Energy Beam (previously called inter-vertebral assessment) by Dual energy x-ray absorptiometry of affected femur

Intervention type: DEVICE
Intervention: DXA Se femur scans (previously called IVA femur)
Description: Single Energy Beam (previously called inter-vertebral assessment) by Dual energy x-ray absorptiometry of affected femur

Intervention type: DEVICE
Intervention: DXA Se femur scans (previously called IVA femur)
Description: Single Energy Beam (previously called inter-vertebral assessment) by Dual energy x-ray absorptiometry of affected femur
Study: NCT03842332

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life Skills and Resilience Program
Description: The 12 week life skills course includes resiliency modules that complement the strengths of participants as they progress toward the development and achievement of personal goals. The first module of the intervention engages youth through a caring/supportive relationship that sets these expectations. Activities are designed to support youth in identifying their existing strengths/skills. The second module explores, with youth, how they can apply and build upon their strengths/skills in the pursuit of self-generated goals. The third module is dedicated to building upon key problem solving skills that are especially important for young adults with autism, including conflict resolution and the management of stressors. The fourth module builds leadership capacity and self-advocacy skills.
Study: NCT02413138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somavaratan (VRS-317)
Description: Long acting recombinant human growth hormone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Somavaratan (VRS-317)
Description: Long acting recombinant human growth hormone
Study: NCT02941549

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epeleuton

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epeleuton
Study: NCT03580551

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: Intervention group participants will receive the home-based DVD chair exercise program, which will include a DVD player, Sit and Be Fit DVD, schedule of exercise sessions, hand weights, exercise balls, resistance bands, exercise log, and satisfaction survey. Participants will be instructed to complete an assigned Sit and Be Fit exercise session once a day (sessions last approximately 30 minutes), five days a week (Monday-Friday) for 8 weeks. During the first 6 weeks, the intervention group will not have contact with the study team, unless to trouble-shoot the DVD or answer questions about exercise sessions. At the end of week 6, the intervention group will be contacted to schedule a post-assessment for the end of week 8, which will include repeating all health measures, except for health status.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Waitlist Control Group
Description: At week 8, waitlist control group will receive the home-based DVD chair exercise program, which will include a DVD player, Sit and Be Fit DVD, schedule of exercise sessions, hand weights, exercise balls, resistance bands, exercise log, and satisfaction survey. The waitlist control group will complete a post-assessment at the end of week 8, which will include all health status measures, except health status. Waitlist control group will be instructed to complete an assigned Sit and Be Fit exercise session once a day (sessions last approximately 30 minutes), five days a week (Monday-Friday) for 8 weeks. Waitlist control group will not have contact with the study team, unless to trouble-shoot the DVD or answer questions about exercise sessions. At the end 14 weeks, waitlist control group will be contacted to schedule a final meeting, and to collect the adherence logs and satisfaction survey. At 16 weeks, the waitlist control group will not receive an additional post-assessment.
Study: NCT03646266

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium Bromide
Description: Titration with rocuronium bromide until tidal volume 6ml/kg PBW
Study: NCT03955926

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: preoperative oral carbohydrate loading
Description: Carbohydrate beverage (12.8% carbohydrates, 50 kcal/100 mL, 290 mOsm/kg) 800 mL is given to the NO-NPO group until 2 hours before surgery
Study: NCT02168998

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clown
Description: Comparison of routine venipuncture with a distraction technique by a medical clown
Study: NCT04121715

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fastigial Nucleus Stimulation
Description: Select mode 3, frequency 136, intensity below 90, ratio 1.0-2.0, based on the patient's no discomfort. The main pole is attached to the bilateral mastoid, and the auxiliary pole is attached to the bilateral internal cave. Non-invasive introduction of bio-electricity into the cerebellar nucleus for stimulation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment
Description: Refer to the Guidelines for Rational Use of Coronary Heart Diseases.rational selection of antiplatelet drugs, statins, etc. according to the patient's condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard treatment
Description: Refer to the Guidelines for Rational Use of Coronary Heart Diseases.rational selection of antiplatelet drugs, statins, etc. according to the patient's condition
Study: NCT01685268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT13387
Description: Regimen 1: AT13387, given as 1-hr intravenous infusion at starting dose of 220 mg/m2 once weekly for 3 weeks in a 4-week cycle. Regimen 2: AT13387, given as 1-hr IV infusion at starting dose of 120 mg/m2 on Day 1 and Day 2 weekly for 3 weeks in a 4-week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT13387
Description: Regimen 1: AT13387, given as 1-hr intravenous infusion at starting dose of 220 mg/m2 once weekly for 3 weeks in a 4-week cycle. Regimen 2: AT13387, given as 1-hr IV infusion at starting dose of 120 mg/m2 on Day 1 and Day 2 weekly for 3 weeks in a 4-week cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abiraterone acetate
Description: 1000 mg PO daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abiraterone acetate
Description: 1000 mg PO daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 5 mg PO twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 5 mg PO twice daily.
Study: NCT03408028

Intervention type: OTHER
Intervention: Medical File consultation
Description: Medical File consultation
Study: NCT03087318

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Physical activity:~* 3 sessions / week at least~* at least during 30 minutes each session~* at least at 50% of the maximal heart rate measured during the exercise stress testing (from the screening)~* during 3 months.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Physical activity:~* 3 sessions / week at least~* at least during 30 minutes each session~* at least at 50% of the maximal heart rate measured during the exercise stress testing (from the screening)~* during 3 months.
Study: NCT00916760

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous monthly treatment
Study: NCT02976987

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cidofovir
Study: NCT06606145

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymphovenous Anastomosis
Description: LVA involves connecting functional lymphatic vessels to nearby veins, allowing for the rerouting of lymphatic fluid into the venous system, thus improving lymphatic drainage.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vascularized Lymph Node Transfer
Description: VLNT involves transferring healthy lymph nodes along with their blood supply to the affected lymphoedematous area, aiding in lymphatic fluid transport and potentially promoting lymphangiogenesis.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined Lymphovenous Anastomosis and Vascularized Lymph Node Transfer
Description: Combined simultaneous surgical intervention during which both VLNT and LVA are performed on the operated limb.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Complex Decongestive Therapy
Description: The current standard of care for most BRCL patients includes conservative measures known as Complex Decongestive Therapy (CDT), consisting of compression therapy with low-stretch bandages, manual lymphatic drainage, exercise, and skincare.
Study: NCT01793337

Intervention type: OTHER
Group type: OTHER
Intervention: Exposure to cold environmental temperature (-20°C)

Intervention type: OTHER
Group type: OTHER
Intervention: Exposure to cold environmental temperature (-20°C)
Study: NCT03209557

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SmartWatch SmokeBeat Application
Description: The SmokeBeat app is a digital health app that allows for the user to monitor their smoking behavior in real time, set smoking cessation goals, and allows investigators, doctors and others using the app with participants to send messages directly related to smoking behavior. The SmokeBeat app, developed by Somatix Inc., will collects time-stamped on hand movements associated with smoking behavior. Participants will receive notifications on their phone and smartwatch when a smoking bout has been detected. In addition this app will deliver daily text messages aimed at improving quit rates among participants. We will be able to create the types of messaging we want to send and to modify when these messages will be sent to all participants. http://somatixinc.com/smokebeat/
Study: NCT06163313

Intervention type: OTHER
Intervention: Observation of patients suffering from kidney stones who undergo endoscopic surgery
Description: Clinical data will therefore be acquired through a collection of medical history, physical examination, blood chemistry and instrumental test reports;
Study: NCT01877070

Intervention type: BEHAVIORAL
Intervention: assessments
Study: NCT02852785

Intervention type: BEHAVIORAL
Intervention: PNF D2 for flexion; low-to-moderate loading condition
Description: Exposure to upper extremity PNF D2 for flexion during low-to-moderate loading condition

Intervention type: BEHAVIORAL
Intervention: PNF D2 for flexion; low-to-moderate loading condition
Description: Exposure to upper extremity PNF D2 for flexion during low-to-moderate loading condition